Fed’s Powell opens door to potential rate cuts at Jackson Hole
Cosmos Health Inc. (NASDAQ:COSM), a company currently valued at $11 million market cap and rated ’FAIR’ on InvestingPro’s Financial Health Score, saw its CEO Grigorios Siokas acquire 85,714 shares of the company’s common stock, according to a recent SEC filing. The shares were acquired at a price of $0.525 each, totaling approximately $44,999. This transaction was part of a debt exchange agreement, where Siokas received the shares in exchange for a $45,000 debt owed to him by the company. Following this acquisition, Siokas now holds a total of 4,115,302 shares in Cosmos Health. The stock, which InvestingPro analysis indicates is currently undervalued, has experienced significant volatility, declining over 50% in the past six months. Discover more insights and 10 additional ProTips for COSM on InvestingPro.
In other recent news, Cosmos Health Inc. has postponed its planned securities offering as it prepares to file its Annual Report for the fiscal year ending December 31, 2024. The company has not specified a new date for the offering, indicating it will proceed after the report is filed. Additionally, Cosmos Health is advancing its weight management product, CCX0722, toward clinical trials, with a market launch anticipated in the first half of 2026. The company is actively engaging with Contract Research Organizations to complete the necessary technical dossier for regulatory submission. In another development, Cosmos Health has filed new patent applications for treatments targeting glioma and hematologic malignancies, expanding its intellectual property portfolio. This move highlights the company’s collaboration with Cloudpharm and the National Hellenic Research Foundation. Furthermore, Cosmos Health has secured a 10-year contract manufacturing agreement with Provident Pharmaceuticals through its subsidiary, Cana Laboratories. This agreement involves the production of 800,000 packs of pharmaceutical products annually. Lastly, Cosmos Health has filed a patent application for a new allergy inflammation treatment, supported by its AI-powered Cloudscreen drug repurposing platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.